 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910» |
- | imipenem/relebactam / Merck (MSD)
Journal: Rapid detection of KPC-producing Enterobacterales by using a modified Carba NP test with imipenem/relebactam. (Pubmed Central) - Dec 5, 2022
The biochemical assay provides very reliable results for detecting KPC-producing Enterobacterales, with a turnaround time of less than 1 hour, minimum handling and no specialized equipment required.
- | meropenem / Generic mfg.
Preclinical, Journal: In vitro and in vivo activity of meropenem+avibactam against MBL-producing carbapenem-resistant Klebsiella pneumoniae. (Pubmed Central) - Nov 27, 2022
To our knowledge, this study is the first report of MEM+AVI collaborating against MBL-producing CRKP strains. Our findings showed that the combination of MEM+AVI has the potential for antibiotic drug development to combat MBL-producing pathogens.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020. (Pubmed Central) - Nov 25, 2022
Moreover, genetic analysis of porin genes showed that 14/16 of KPC-Kp resistant isolates possessed a truncated OmpK35 and glycine (G) and aspartic acid (D) insertions at positions 134-135 within OmpK36, whereas 2/16 displayed truncated OmpK35 and OmpK36 porins. Novel βL-βLICs are promising agents against KPC-Kp infections; however, the emergence of resistance to these agents highlights the need for continuous surveillance and application of enhanced antimicrobial stewardship.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap
Preclinical, Journal: In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Pseudomonas aeruginosa in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) in 2020. (Pubmed Central) - Nov 8, 2022
Novel βL-βLICs are promising agents against KPC-Kp infections; however, the emergence of resistance to these agents highlights the need for continuous surveillance and application of enhanced antimicrobial stewardship. No abstract available
- || imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
also curious about potential empirical activity of ceftazidime/avibactam and imipenem/relebactam on this isolate based on this suceptibility pattern? (Twitter) - Nov 4, 2022
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies). (Pubmed Central) - Nov 2, 2022
No abstract available Microbiological results reinforce imipenem/relebactam as a potential option to treat cUTI, cIAI and LRTI caused by MDR/XDR P. aeruginosa isolates, except for GES-13 and VIM producers.
- | imipenem/relebactam / Merck (MSD)
Journal: Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies). (Pubmed Central) - Oct 29, 2022
Molecular characterization by whole-genome sequencing shows that most of the resistant isolates produced specific carbapenemase, such as OXA-48 or metalo-betalactamases. Our study updates the activity of imipenem-relebactam in light of current epidemiology in a hospital setting in which the use of this combination is needed due to the presence of infections due to multidrug-resistant isolates.
- | Journal: Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant Enterobacterales. (Pubmed Central) - Oct 27, 2022
When increasing inoculum to 10 CFU/mL, all of the molecules were impacted, particularly cefiderocol and imipenem-relebactam, while others, such as ceftazidime-avibactam, remain mildly affected. Our in vitro results deserved to be confirmed in vivo.
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae. (Pubmed Central) - Oct 21, 2022
Complementation assays showed that OmpK36 plays a major role in IPM-REL resistance as well resistance to other ß-lactams and β-lactam/ß-lactamase inhibitor combinations. Overall, this study showed that (i) IPM-REL resistant strains can be obtained from CAZ-AVI-susceptible or -resistant KPC producers, (ii) selection of IPM-REL resistance has a collateral effect on MEM-VAB susceptibility - indicative of shared resistance mechanisms, (iii) and mutations in the KPC sequence may be obtained using IPM-REL selection leading to the possibility of vertical and horizontal transfer of this resistance trait.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal, Combination therapy: Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa. (Pubmed Central) - Oct 15, 2022
However, susceptibility to ceftazidime was significantly improved with the addition of avibactam (p < 0.01), and the susceptibility to C/T was improved compared to piperacillin/tazobactam (p < 0.05) These data provide in vitro evidence that I-R may not be any more effective than imipenem monotherapy against MDR CFPA. The pattern of susceptibility observed for CZA and C/T in the current study was similar to data previously reported for non-CF-associated MDR P. aeruginosa.
- In vitro antibacterial activity of cefiderocol against a multinational collection of Pseudomonas aeruginosa isolates from people with cystic fibrosis: SENTRY 2020–2021 (Exhibition Hall) - Oct 8, 2022 - Abstract #NACFC2022NACFC_1058;
aeruginosaisolates collected from PwCF. Results from these studiessuggest that cefiderocol could provide an important treatment option forP.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents. (Pubmed Central) - Oct 6, 2022
A decline in carbapenemase production was noticed in US hospitals in the 5-year period analysed in this study. New β-lactam/β-lactamase inhibitor combinations tested had good activity against CNSE isolates.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48. (Pubmed Central) - Oct 5, 2022
Data demonstrate that current imipenem/relebactam and ceftazidime/avibactam CLSI breakpoints are appropriate. Data also suggest that higher meropenem/vaborbactam breakpoints relative to meropenem can translate to potentially poor clinical outcomes in patients infected with OXA-48-harbouring isolates.
- | Journal: Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa. (Pubmed Central) - Oct 5, 2022
Cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam show promising and complementary in vitro activity against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant P. aeruginosa. These agents may represent potential therapeutic options for ceftolozane/tazobactam- and ceftazidime/avibactam-resistant P. aeruginosa infections.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Susceptibility of OXA-48-producing Enterobacterales to imipenem-relebactam, meropenem-vaborbactam and ceftazidime-avibactam. (Pubmed Central) - Sep 29, 2022
These agents may represent potential therapeutic options for ceftolozane/tazobactam- and ceftazidime/avibactam-resistant P. aeruginosa infections. This study highlighted the lack of benefit in vitro for carbapenem-inhibitor combination compared to carbapenem alone on OXA-48-producing isolates as well as the difficulties to compared molecules since carbapenem-inhibitor combinations were not developed with the same dosage of carbapenem.
- || Retrospective data, Review, Journal: Evaluating the clinical effectiveness of new beta-lactam/beta-lactamase inhibitor combination antibiotics: A systematic literature review and meta-analysis. (Pubmed Central) - Sep 29, 2022
C/T, C/A, I/R, and M/V are not inferior to standard therapies for treating various complicated infections, but they may have greater clinical success for treating MDRPA and CRE infections. More studies that evaluate the use of these antibiotics for drug-resistant infections are needed to determine their effectiveness.
- || imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Review, Journal: Current Positioning against Severe Infections Due to Klebsiella pneumoniae in Hospitalized Adults. (Pubmed Central) - Sep 25, 2022
Moreover, we reviewed and updated the most important clinical entities and the new antibiotic treatments recently developed. After analysis of the priorities outlined, this group of experts established a series of recommendations and designed a management algorithm.
- | imipenem/relebactam / Merck (MSD)
Journal: Evolution of imipenem-relebactam resistance following treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia. (Pubmed Central) - Sep 14, 2022
Genome sequence analysis identified treatment-emergent mutations in MexAB-OprM and/or MexEF-OprN efflux operons that arose independently in each patient and across distinct P. aeruginosa sequence types. Testing with efflux-inhibitor PAβN restored imipenem-relebactam susceptibility.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically-ill patient: K.pneumoniae co-producing OXA181 and KPC-121. (Pubmed Central) - Sep 14, 2022
The description of the genome of KPC-Kp cross-resistant to novel βL-βLICs and cefiderocol reveals the presence of numerous antimicrobial resistance genes including bla and novel variant bla. The characterization of this multidrug-resistant phenotype provides evidence that needs further attention and monitoring of such MDR clinical isolates.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019. (Pubmed Central) - Sep 10, 2022
IMPORTANCE After testing cefiderocol against a large collection of clinical isolates of highly antimicrobial-resistant Pseudomonas aeruginosa, we report that cefiderocol is active versus 97.4% of extensively drug-resistant (XDR) and 97.9% of multidrug-resistant (MDR) (n = 771) isolates. These data show that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa.
- Transcriptional Variation of Adhesion and Biofilm Genes in CTX-M-15-Expressing Klebsiella pneumoniae (144 ABC) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2595;
- Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex Clinical Isolates Causing Infection in United States Hospitals (2020-2021) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2281;
- In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020-2021) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2280;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
Temporal and Geographical Prevalence of Carbapenem-Resistant Pseudomonas aeruginosa and the In Vitro Activity of Ceftolozane/Tazobactam and Comparators in Taiwan – SMART 2012-2020 (Virtual) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_1732;
- imipenem/relebactam / Merck (MSD)
Imipenem-Relebactam activity and genotypic characteristics of Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa Isolates from Latin American Infections - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017 – 2020 (Virtual) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_802;
- Activity of Novel b-Lactam/b-Lactamase Inhibitor (BL/BLI) Combinations Against AmpC-Producing Species Collected in United States Hospitals (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_778;
- OMNIvance (xeruborbactam) / Qpex Biopharma
Xeruborbactam (QPX) Potentiates the Activity of β-Lactam (BL) Antibiotics Against a Diverse Group of Highly Drug-Resistant Enterobacterales (ENT) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_777;
- Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021 (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_774;
- National Surveillance of Gram-negative Bacteria in Qatar, the Study for Monitoring of Antimicrobial Resistance Trends (SMART): from 2017 to 2019 (Virtual) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_765;
- In Vitro Activity of Cefiderocol against IMP-Producing Enterobacterales Isolated in Japan (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_761;
- imipenem/relebactam / Merck (MSD)
In Vitro Activity of Imipenem/Relebactam against Class C β-lactamase-Positive Enterobacterales in the Asia/Pacific Region: SMART 2018-2020 (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_758;
- OMNIvance (xeruborbactam) / Qpex Biopharma
Meropenem-Xeruborbactam: In Vitro Potency against Gram-Negative Bacteria in Comparison with Marketed and Investigational Beta-lactam (BL)/Beta-lactamase Inhibitor (BLI) Combinations (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_733;
- aztreonam-avibactam (PF-06947387) / Pfizer, AbbVie
Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) collected in Hospitals from Europe, Asia, and Latin America (2019-2021) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_728;
- imipenem/relebactam / Merck (MSD)
Activity of Imipenem/Relebactam and Comparators Against Gram-Negative MDR and DTR Pathogens from Patients with Respiratory and Bloodstream Infections – SMART United States 2018-2020 (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_711;
- || Clinical data, Review, Journal: Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. (Pubmed Central) - Aug 24, 2022
Other clinically effective combinations include meropenem-vaborbactam (MVB), ceftolozane-tazobactam (C/T) and imipenem-relebactam (I-R)...Susceptible CRE infections can be treated with fluoroquinolones, aminoglycosides or fosfomycin, but alternatives include CZA, MVB, I-R, cefiderocol, tigecycline and eravacycline...Currently, no single agent can treat all MDR-GNB infections, but new β-lactam-β-lactamase inhibitor combinations are often effective for different infection sites, and, when used appropriately, have the potential to improve outcomes. This article reviews clinical studies investigating novel β-lactam approaches for treatment of MDR-GNB infections.
- | Journal: Characterization of resistance to newer antimicrobials among carbapenem-resistant Klebsiella pneumoniae in the post-acute-care setting. (Pubmed Central) - Jul 30, 2022
Meropenem-vaborbactam and imipenem-relebactam nonsusceptibility were observed among 9.9% and 9.1% of isolates, respectively. Nonsusceptibility to ceftazidime-avibactam (1.1%) and plazomicin (0.8%) were uncommon.
- || imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Review, Journal: The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms. (Pubmed Central) - Jul 24, 2022
Despite this, susceptibility testing is warranted due to variable activity against certain β-lactamases (e.g., oxacillinases) and the presence of acquired resistance mechanisms in some isolates. Here, we discuss what we know about these new antimicrobial agents and how to navigate implementation of susceptibility testing and reporting of these agents in clinical laboratories.
- | imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Journal: New Perspectives on Antimicrobial Agents: Imipenem-Relebactam. (Pubmed Central) - Jul 23, 2022
Further comparative PK/PD and clinical studies are warranted to determine the optimal role of I/R, alone and in combination, for the treatment of patients with highly resistant Gram-negative infections. Until further data are available, I/R is a potential treatment for patients with CR-NME and DTR P. aeruginosa infections when the benefits outweigh the risks.
- | Journal: Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates. (Pubmed Central) - Jul 14, 2022
Selection among novel agents requires a nuanced understanding of the molecular epidemiology of CRE. This work provides insights into the comparative activity of novel agents and the additive value of a second antibiotic for empiric antibiotic decision making.
- || Ceftaz/avi without aztreonam, ceftolozane/tazobactam or imipenem/relebactam are not going to work against an NDM producer. (Twitter) - Jul 14, 2022
- | Journal: Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. (Pubmed Central) - Jun 30, 2022
Recently, novel BL and BL/BLI combinations have become available that have shown potent in vitro activity against CR-GNB and have attracted much interest as novel, less toxic, and possibly more efficacious options for the treatment of CR-GNB VAP compared with previous standard of care. Besides randomized controlled trials, a good solution to enrich our knowledge on how to use these novel agents at best in the near future, while at the same time remaining adherent to current evidence-based guidelines, is to improve our collaboration to conduct larger multinational observational studies to collect sufficiently large populations treated in real life with those novel agents for which guidelines currently do not provide a recommendation (in favor or against) for certain causative organisms.
- | relebactam (MK-7655) / Merck (MSD)
Journal: Klebsiella pneumoniae Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio. (Pubmed Central) - Jun 25, 2022
(2) At HI, carbapenem/relebactam combination MICs increased to levels associated with carbapenem resistance. (3) Combination MICs determined at pharmacokinetic-based carbapenem-to-inhibitor concentration ratios predict susceptibility elevations at HI in KPC-producing K. pneumoniae.
- |||| Clinical: #IDTwitter as a follow up. R to ceftazidime-avibactam and I to ceftolozane-tazobactam. I switched to imipenem-relebactam and kept eravacycline. Patients is slowly improving. Not sure if I should add levofloxacin (Twitter) - Jun 25, 2022
- | imipenem/relebactam / Merck (MSD), Recarbrio (relebactam/imepenem/cilastatin) / Merck (MSD)
Preclinical, Journal: In vitro activity of imipenem/relebactam and comparator agents against clinical bacterial isolates from patients with cancer. (Pubmed Central) - Jun 22, 2022
(3) Combination MICs determined at pharmacokinetic-based carbapenem-to-inhibitor concentration ratios predict susceptibility elevations at HI in KPC-producing K. pneumoniae. Its in vitro activity indicates that IMI/REL might have a role to play in the treatment of Gram-negative infections in patients with cancer.
- || imipenem/relebactam / Merck (MSD)
Imipenem relebactam is recommended to administer as 3 h infusion. Does imipenem have stability in infusion solution for 3 h? (Twitter) - Jun 21, 2022
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal, Combination therapy: In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens. (Pubmed Central) - Jun 9, 2022
The FICI revealed the synergistic (60%, 6/10) and additive (40%, 4/10) effects of imipenem-relebactam in combination with fosfomycin, wherein synergistic activity was found against all tested Klebsiella pneumoniae and Acinetobacter baumannii. Imipenem-relebactam may be a new alternative for carbapenem-resistant Gram-negative pathogens infections and the combination of imipenem-relebactam and fosfomycin warrants further exploration.
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In vitro activity of imipenem/relebactam plus aztreonam against metallo-β-lactamase producing, OprD-deficient Pseudomonas aeruginosa with varying levels of Pseudomonas-derived cephalosporinase production. (Pubmed Central) - Jun 8, 2022
I/R plus ATM appears to exhibit synergy for some MBL-producing P. aeruginosa at physiological concentrations. Further study of the effect of dynamic concentrations is needed to fully understand the utility of this combination.
- imipenem/relebactam / Merck (MSD)
High Throughput Screening Reveals Beta-Lactamase Synthesis Regulator / Muropeptide Transporter (ampG) as a Candidate Gene of Carbapenem Resistance in Klebsiella Pneumoniae (Exhibit and Poster Hall) - Jun 4, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_2769;
Overexpression of ampG in the mutant genetic background resulted in a 2-4 fold meropenem, ceftazidime or cefiderocol MIC increase compared to the mutant alone. In conclusion, ampG may play a role in resistance for beta-lactams including carbapenems in the pathogen K. pneumoniae.
- imipenem/relebactam / Merck (MSD)
In Vitro Activity of Imipenem-Relebactam Against Various Resistance Phenotypes/Genotypes of Enterobacterales and Pseudomonas Aeruginosa Isolated from Patients Across Canada: CANWARD 2016-2021 (Exhibit and Poster Hall) - Jun 4, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_2681;
IMI-REL was highly active (MIC90s, 0.25-1 μg/ml) against commonly encountered species of Enterobacterales (excluding Morganellaceae) and P. aeruginosa (MIC90, 2 μg/ml), including ESBL-positive E. coli and K. pneumoniae, and AmpC-positive E. coli. IMI-REL was 4-fold more active than IMI against IMI-R Enterobacterales and 4-8 fold more active than IMI against P. aeruginosa.
- Evaluation and Verification of the Sensititre MDRGN2F Panel (Exhibit and Poster Hall) - Jun 4, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_2634;
The Sensititre MDRGN2F plate has facilitated a more streamlined AST workflow for various known MDROs in our clinical microbiology laboratory, resulting in comprehensive susceptibility testing results for applicable antimicrobial agents. In lieu of using multiple AST methods (Kirby Bauer, E-test, reference lab testing), we are now able to test the recently approved β-lactamase inhibitors on one panel.